CompletedPhase 4

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

United States13 participantsStarted 2019-02-08

Plain-language summary

Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria : * Male and female adult participants who had been treated with LEMTRADA, with development of ITP subsequent to treatment. Participants does not need to be currently on LEMTRADA treatment. * Participants who had signed the study ICF. Exclusion criteria: \- Not applicable The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

What they're measuring

Number of Participants Who Provided Whole Blood Samples for DNA Extraction and Analysis

Timeframe: Baseline (Day 1)

Trial details

NCT IDNCT03784898

SponsorGenzyme, a Sanofi Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-12-11

Results submitted2020-07-02

View on ClinicalTrials.gov More Multiple Sclerosis trials